

February 04, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Wednesday, February 04, 2026

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject; we, Zota Health Care Limited (“the Company”), would like to inform you that the Board of Directors of the Company in its Meeting held on Wednesday, February 04, 2026 at 05:00 P.M. at Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have *inter alia*, discussed and approved the following business:

1. Considered and approved Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025 along with the Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (**Annexure -1**).

The Unaudited Standalone and Consolidated Financial Results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company's website at www.zotahealthcare.com.

2. Approved for acquisition of 58,827 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is annexed herewith as (**Annexure-2**).
3. Further to our intimation dated January 30, 2026 the Board has approved for acquisition of 100% stake in M/s Curexis Ventures Private Limited. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is annexed herewith as (**Annexure-3**).

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

4. Considered and approved the constitution of Risk Management Committee with the following members:

- i.Mr. Moxesh Ketanbhai Zota, (Managing Director) — Chairperson
- ii.Mr. Himanshu Muktilal Zota, (Whole- time Director) — Member
- iii.Mr. Dhaval Chandubhai Patwa, (Independent Director) — Member

The Board meeting concluded at 6:15 P.M.

This is for your information and record.

Thanking you,
Yours faithfully,
For Zota Health Care Limited

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat
Encl: a/a

PRADEEP K SINGHI & ASSOCIATES

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
 The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") **for the quarter and nine months ended December 31, 2025** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing

PRADEEP K SINGHI & ASSOCIATES

CHARTERED ACCOUNTANTS

Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pradeep K Singhi & Associates

Chartered Accountants

FRN : 0126027W

Date: 04/02/2026

Place: Surat

Pradeep Kumar Singhi

(Partner)


UDIN: 26024612SHEJZT3619

Unaudited Standalone Financial Results for the quarter and Nine months ended 31st December, 2025

Particulars		Quarter Ended			(Amount in ₹ Lakhs, except per share data)	
		31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)
I.	Revenue from Operations	10887.55	9942.42	6813.08	28630.67	17934.36
II.	Other Income	379.76	326.71	168.91	929.86	312.81
III.	Total Income	11267.31	10269.13	6981.99	29560.53	18247.17
IV.	Expenses:					
	Cost of Materials Consumed	606.62	288.85	303.90	1386.00	1013.73
	Purchases of Stock-in-Trade	6491.41	4810.83	4699.98	14744.45	9952.55
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1038.35)	336.39	(943.99)	(165.06)	(168.56)
	Employee Benefit Expenses	1318.28	1025.36	854.97	3341.23	2228.23
	Finance Costs	4.57	8.67	3.83	16.91	97.66
	Depreciation / Amortisation and Depletion Expense	99.38	91.04	81.75	270.10	222.74
	Other Expenses	2682.80	2400.92	1767.41	6702.68	4158.43
	Total Expenses	10164.70	8962.07	6767.84	26296.31	17504.78
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	1102.60	1307.05	214.15	3264.21	742.38
VI.	Exceptional Items	-	-	-	-	1184.33
VII.	Profit/(loss) before tax	1102.60	1307.05	214.15	3264.21	742.38
VIII.	Tax Expense:					
	(1) Current tax	275.50	332.17	(15.23)	831.35	134.22
	(1.1) I.T. & DD Tax Provision Created Short/ excess	(10.95)	(2.49)	(10.95)	(2.49)	(2.49)
	(2) Deferred Tax	(237.55)	15.97	(24.10)	(262.03)	(9.26)
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	600.50	990.85	207.77	2181.78	601.39
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-
XIII.	Profit/ (Loss) for the period	600.50	990.85	207.77	2181.78	601.39
XIV.	Other Comprehensive Income					
	A (i) Items that will not be reclassified to Statement of profit and loss	35.88	-	22.94	19.79	12.98
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(9.03)	-	(5.77)	(4.98)	(3.27)
	B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-
	Other comprehensive income for the period, net of tax	26.85	-	17.17	14.81	9.71
	Total comprehensive income for the period (XIII + XIV)	627.35	990.85	224.94	2196.59	611.10
	Paid-up Equity Share Capital	3377.39	3064.38	2757.10	3377.39	2757.10
	Other Equity					
	Earnings per equity share of face value of ₹ 10 each					
	(1) Basic (in ₹)	1.92	3.27	0.76	7.09	2.23
	(2) Diluted (in ₹)	1.87	3.12	0.70	6.91	2.07

* denotes figures less than a lakh

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Company Secretary
Ashvin Varyia
Date: 04-02-2026
Place : Surat


Chief Financial Officer
Viral Mandviwala


Group Chief Executive Officer
Sujit Paul



For Pradeep K. Singh & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singh
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

PRADEEP K SINGHI & ASSOCIATES

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and nine months ended December 31, 2025** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)
- b. Zota Healthcare Lanka (Pvt.) Ltd. (Wholly Owned Subsidiary)

PRADEEP K SINGHI & ASSOCIATES

CHARTERED ACCOUNTANTS

- c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- d. Zota Nex Tech Limited (Wholly Owned Subsidiary)
- e. Everyday Herbal Beauty Care Private Limited (Subsidiary)
- f. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total revenues of Rs. 7744.26 Lakhs and Rs.19425.29 Lakhs, total net profit/(loss) after tax of Rs. (3450.69) Lakhs and Rs. (8078.92) Lakhs and total comprehensive income of Rs. (3391.22) Lakhs and Rs. (8017.92) Lakhs, respectively for the quarter and nine months ended December 31, 2025 , as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

**For Pradeep K Singh & Associates
Chartered Accountants
FRN : 0126027W**

Date: 04/02/2026

Place: Surat

**Pradeep Kumar Singh
(Partner)
UDIN: 26024612CISJDG7606**

Particulars	Quarter Ended			Nine months ended		Year Ended
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	14295.14	12894.82	7212.38	37548.22	19570.03	29297.48
II. Other Income	171.69	163.65	50.59	422.94	106.65	206.80
III. Total Income	14466.83	13058.47	7262.97	37971.16	19676.68	29504.28
IV. Expenses:						
Cost of Materials Consumed	606.62	288.85	303.90	1386.00	1013.73	1622.76
Purchases of Stock-in-Trade	7703.59	5847.62	4808.81	17736.81	10036.34	16257.53
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(2632.89)	(891.91)	(1929.48)	(3687.65)	(2107.23)	(4149.96)
Employee Benefit Expenses	5252.46	3819.72	2381.99	12389.49	6012.99	8606.62
Finance Costs	497.14	382.82	157.40	1203.87	732.54	1078.34
Depreciation / Amortisation and Depletion Expense	2225.55	1850.79	1134.53	5544.18	2888.11	4319.61
Other Expenses	3409.48	3198.48	2254.22	8739.98	5434.14	7533.82
Total Expenses	17061.94	14496.38	9111.37	43312.66	24010.62	35268.71
V. Profit before Exceptional items and tax from continuing operations (III-IV)	(2595.11)	(1437.91)	(1848.40)	(5341.50)	(4333.94)	(5764.43)
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(loss) before tax	(2595.11)	(1437.91)	(1848.40)	(5341.50)	(4333.94)	(5764.43)
VIII. Tax Expense:						
(1) Current tax	269.30	317.80	(15.23)	831.35	134.22	338.13
(1.1) I.T. & DD Tax Provision Created Short/ excess	(10.95)	-	(2.49)	(10.95)	(2.49)	(2.49)
(2) Deferred Tax	(110.92)	136.33	(63.86)	200.36	80.65	426.19
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(2964.38)	(1619.38)	(1894.54)	(5961.55)	(4385.02)	(5673.89)
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-	-
XIII. Profit/ (Loss) for the period	(2964.38)	(1619.38)	(1894.54)	(5961.55)	(4385.02)	(5673.89)
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	115.18	-	34.81	101.14	24.41	40.31
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(28.86)	-	(8.74)	(25.33)	(6.13)	(10.11)
B (i) Items that will be reclassified to Statement of profit and loss	-	*	0.03	0.01	(0.04)	(0.05)
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	*	*	*	*	0.01
Other comprehensive income for the period, net of tax	86.32	(30.67)	26.09	75.82	18.26	30.16
Total comprehensive income for the period (XIII + XIV)	(2878.06)	(1619.38)	(1868.45)	(5885.73)	(4366.77)	(5643.73)
Profit attributable to:						
Owners of the parent	(2950.32)	(1594.88)	(1868.17)	(5976.79)	(4350.80)	(5639.84)
Non-controlling interest	(14.06)	(24.49)	(26.37)	15.24	(34.23)	(34.05)
Other comprehensive income attributable to:						
Owners of the parent	87.54	0.36	26.09	75.82	18.26	30.16
Non-controlling interest	(1.22)	(0.36)	-	-	-	-
Total Comprehensive Income attributable to:	(2862.79)	(1594.53)	(1842.08)	(5900.97)	(4332.54)	(5609.68)
Owners of the parent	(15.27)	(24.85)	(26.37)	15.24	(34.23)	(34.05)
Paid-up Equity Share Capital	3377.39	3064.38	2757.10	3377.39	2757.10	2863.50
Other Equity	-	-	-	-	-	19504.98
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	-9.44	-5.26	(6.80)	(19.42)	(16.12)	(20.68)
(2) Diluted (in ₹)	-9.21	(5.02)	(6.31)	(18.94)	(14.96)	(19.06)

* denotes figures less than a lakh
For and on behalf of the Board



(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)



(Managing Director)
Moxesh K. Zota
(Din : 07625219)



Company Secretary Chief Financial Officer Group Chief Executive Officer
Ashvin Varya Viral Mandiwala Sujit Patel

Date: 04-02-2026
Place: Surat

For Pradeep K. Singh & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singh
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj) India
Ph: +91 261 2397122

Notes:

1. The above financial results for the quarter and nine months ended December 31, 2025 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 04, 2026.
2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2025.
4. During the quarter, upon receipt of balance 75% amount i.e. Rs. 381.75/- per warrant of the warrants issue price, the Board of Directors of the Company has issued equity shares upon conversion of warrants as below:

Date of Allotment	No. of Equity Shares Issued
October 02, 2025	95,921
November 10, 2025	1,51,537

5. During the quarter, upon receipt of balance 75% amount i.e. Rs. 615.00/- per warrant of the warrants issue price, the Board of Directors of the Company has on December 24, 2025 allotted 6,02,500 equity shares upon conversion of warrants.
6. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
7. During the quarter, the Company has approved the issue and allotment of 22,80,130 Equity Shares to eligible QIBs at the issue price of Rs. 1,535/- per Equity Share including a premium of Rs. 1,525/- per Equity Share, which includes a discount of Rs. 80.28/- i.e., 4.97 % of the floor price, aggregating to Rs. 3,49,99,99,550/-, pursuant to the QIP in accordance with provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.
8. The consolidated results include the result of following companies:
 - i) Zota Healthcare Lanka (Pvt) Ltd
 - ii) Davaindia Health Mart Limited
 - iii) Zota Nex Tech Limited
9. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 20,346.80 lakhs and a corresponding Lease Liability of Rs. 21,883.20 lakhs as at December 31, 2025. The impact of this on the consolidated profit for the quarter and nine months ended December 31, 2025 is Rs. 290.65 lakhs and Rs. 713.74 lakhs respectively.
10. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj) India
Ph: +91 261 2397122



Annexure-2

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc.	<p>i. Name of the Target Entity: Davaindia Health Mart Limited ("DIHML")</p> <p>ii. Business of the Target Entity: To operate retail Generic Pharmacy chain under Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy.</p> <p>iii. Financial details: as per the audited financial statements for the Financial Year 2024-25, the turnover of DIHML was Rs. 109.93 crores and the total paid up share capital was Rs. 2.65 crores.</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The acquisition does not fall within related party transactions. The promoter/ promoter group/ group companies do not have any interest in DIHML.
Industry to which the entity being acquired belongs	Pharmaceutical
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has made further investment in DIHML as a part of strategic investment, expansion of COCO stores of Davaindia by WOS and working capital requirements of WOS. Post to this acquisition, DIHML continues to remain as the WOS of the Company.
Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
Indicative time period for completion of the acquisition	On February 04, 2026 the Company has acquired the said 58,827 equity shares of DIHML.
Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration by way of acquisition of Equity Shares
Cost of acquisition or the price at which the shares are acquired	Cost of acquisition for the right issue of 58,827 Equity Shares is Rs. 4300/- per equity share (including premium of Rs. 4290/- per equity share) aggregating to Rs. 25,29,56,100/-.
Percentage of shareholding / control acquired and / or number of shares acquired	The company has further acquired 58,827 equity shares of DIHML. Post to this acquisition, the DIHML continues to remain as the WOS of the Company.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>DIHML was incorporated on January 01, 2020, domiciled in India; operating COCO stores of Davaindia Generic Pharmacy having store presence in 25 states and 5 Union Territories with 1438 stores as at December 31, 2025 and offering 2000+ SKUs inclusive of Medicines, Ayurvedic, Cosmetics, Nutraceutical and OTC products.</p> <p>During last three financial years, the details of turnover of DIHML were as follows:</p> <p>FY 2024-25 Rs. 109.93 crores FY 2023-24 Rs. 44.77 crores FY 2022-23 Rs. 14.61 crores</p>

Annexure-3

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc.	<p>iv. Name of the Target Entity: Curexis Ventures Private Limited ('Curexis')</p> <p>v. Business of the Target Entity: established as a drug manufacturing, development, and marketing company. CUREXIS is engaged in the business of running retail pharmacy stores under the brand name of "SKIA" offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products.</p> <p>vi. Financial details: as per the financial statements for the Financial Year 2024-25, the turnover of Curexis was Rs. NIL and as per the interim financial statements for the nine months ended December 31, 2025 the turnover was Rs. 0.28 lakhs and total paid up share capital was Rs. 1.00 lakh.</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Yes, the equity shares have been acquired from Mr. Sushant Bhattacharya, Senior Managerial Personnel of the M/s Zota Health Care Limited, and has been done at arm's length basis. Except to this, none of promoter/ promoter group/ other group companies have any interest in the said acquisition.
Industry to which the entity being acquired belongs	Pharmaceutical
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To expand the footprint of the Company in the retail generic pharmacy chain segment.
Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
Indicative time period for completion of the acquisition	On February 04, 2026, the Company has acquired the said 1,00,000 equity shares of Curexis.
Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration by way of acquisition of Equity Shares.
Cost of acquisition or the price at which the shares are acquired	Cost of acquisition for 1,00,000 equity shares is Rs. 10/- per equity share aggregating to Rs. 10,00,000/-.
Percentage of shareholding / control acquired and / or number of shares acquired	The Company has acquired 1,00,000 equity shares of Curexis. Post to this acquisition, the Company's shareholding is 100% in Curexis.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Curexis was incorporated on February 25, 2025, domiciled in India; engaged in drug manufacturing, development, and marketing company. CUREXIS is engaged in the business of running retail pharmacy stores under the brand name of "SKIA" offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products.</p> <p>During last three financial years, the details of turnover of Curexis were as follows:</p> <p>FY 2024-25: Rs. NIL</p> <p>FY 2023-24: N.A.</p> <p>FY 2022-23: N.A.</p>